

Herzinsuffizienz Referenzen



Referenzen

1. US Department of Health and Human Services. Agency for Health Care Policy and Research. Acute Pain Management: operative or medical procedures and trauma. Rockville (MD): The Agency; 1993. Clinical Practice Guideline No.1. AHCPR Publication No.92-0023. p.107.
2. Scottish Intercollegiate Guidelines Network. Diagnosis and treatment of heart failure due to left ventricular systolic dysfunction. Edinburgh, SIGN; 1999
3. Leitlinie Herzinsuffizienz Version 5/1999, medizinisches Informationsmanagement der Universität Witten/Herdecke 1999
4. Leitlinien zur Therapie der chronischen Herzinsuffizienz der deutschen Gesellschaft für Kardiologie – Herz – und Kreislaufforschung. Zeitschrift für Kardiologie 1998; 87: 645-661
5. Guidelines for the diagnosis of heart failure. The Task Force on Heart Failure of the European Society of Cardiology. Eur Heart J 1995; 16: 741-51.
6. The treatment of heart failure. Task Force of the Working Group on Heart Failure of the European Society of Cardiology. Eur Heart J 1997; 18: 736-53.
7. Guidelines for the evaluation and management of heart failure. Report of the American College of Cardiology / American Heart Association Task Force on Practice Guidelines (Committee on Evaluation and Management of Heart Failure). Circulation 1995; 92: 2764-84.
8. McMurray J, Gyarfás I, Wenger NK, Al Nozha MM, Boskis B, Bristow M, et al. Concise guide to the management of heart failure. Am J Geriatr Cardiol 1996; 5: 13-30.
9. Eccles M, Freemantle N, Mason J. North of England evidence-based guideline development project: guideline for angiotensin convertin enzyme inhibitors in primary care management of adults with symptomatic heart failure. BMJ 1998; 316: 1369-75.
10. Packer M, Cohn JN. Consensus recommendations for the management of chronic heart failure. Am J Cardiol 1999; 83(2A): A1-A38.
11. US Department of Health and Human Services. Agency for Health Care Policy and Research. Heart failure: evaluation and care of patients with left-ventricular systolic dysfunction. Rockville, The Agency 1994. Clinical Practice Guideline No. 11. AHCPR Publication No. 94-0612.
12. Johnstone DE, Abdulla A, Arnold JM, Bernstein V, Bourassa M, Brophy J, et al. Diagnosis and management of heart failure. Canadian Cardiovascular Society. Can J Cardiol 1994; 10: 613-31.
13. Vantrimpont P, Rouleau JL. Medical treatment of heart failure: The Canadian Cardiovascular Society's Consensus Conference Revisited. Cardiovasc Drugs Ther 1997; 10: 711-6.
14. The National Heart Foundation of New Zealand, Cardiac Society of Australia and New Zealand and the Royal New Zealand College of General Practitioners Working Party. New Zealand guidelines for the management of chronic heart failure. NZ Med J 1997; 110: 99-107.
15. Eccles M, Freemantle N, Mason J. North of England evidence based development project: guideline for angiotensin converting enzyme inhibitors in primary care management of adults with symptomatic heart failure. BMJ 1998; 316: 1369-75
16. McKelvie, R. S. Herzinsuffizienz. Aus: F. Godlee (Hrsg.) Clinical Evidence, 1. Auflage, Verlag Hans Huber, Bern 2000: 113-128.
17. HFSA. Heart Failure Society of American practice guidelines. HFSA guidelines for management of patients with heart failure caused by left ventricular systolic dysfunction-pharmacological approaches. J Card Fail 1999; 5(4): 357-82.

18. Betkowski, A. S. and P. J. Hauptman. Update on recent clinical trials in congestive heart failure. *Curr Opin Cardiol* 2000; 15(4): 293-303.
19. Erdmann, E. The management of heart failure--an overview. *Basic Res Cardiol* 2000; 95 (Suppl 1): I3-7.
20. *Diseases of the Heart and Blood Vessels - Nomenclature and Criteria for Diagnosis*, 6th edition, Boston, Little Brown and Company, 1964.
21. Harlan WR, Oberman A, Grimm R, Rosati RA. Chronic congestive heart failure in coronary artery disease: clinical criteria. *Ann Intern Med* 1977; 86: 133-8.
22. Davie AP, Francis CM, Caruana L, Sutherland GR, McMurray JJ. Assessing diagnosis in heart failure: which features are any use? *Q J M* 1997; 90: 335-9.
23. Chakko S, Woska D, Martinez H, de Marchena E, Futterman L, Kessler KM, et al. Clinical, radiographic, and haemodynamic correlations in chronic congestive heart failure: conflicting results may lead to inappropriate care. *Am J Med* 1991; 90: 353-9.
24. Stevenson LW, Perloff JK. The limited reliability of physical signs for estimating haemodynamics in chronic heart failure. *JAMA* 1989; 261: 884-8.
25. Badgett RG, Lucey CR, Mulrow CD. Can the clinical examination diagnose left-sided heart failure in adults? *JAMA* 1997; 277: 1712-9.
26. Echeverria HH, Bilsker MS, Myerburg RJ, Kessler KM. Congestive heart failure: echocardiographic insights. *Am J Med* 1983; 75: 750-5.
27. Teerlink JR, Goldhaber SZ, Pfeffer MA. An overview of contemporary etiologies of congestive heart failure. *Am Heart J* 1991; 121: 1852-3.
28. Butman SM, Ewy GA, Standen JR, Kern KB, Hahn E. Bedside cardiovascular examination in patients with severe chronic heart failure: importance of rest on inducible jugular venous distension. *J Am Coll Cardiol* 1993; 22: 968-74.
29. O'Neill TW, Barry M, Smith M, Graham IM. Diagnostic value of the apex beat. *Lancet* 1989;1:410-1.
30. Kalon KL, et al. Survival after the onset of congestive heart failure in Framingham Heart Study subjects. *Circulation*. 1993;88:107-115.
31. Leitlinien zur Therapie der chronischen Herzinsuffizienz herausgegeben vom Vorstand der Deutschen Gesellschaft für Kardiologie - Herz-und Kreislaufforschung bearbeitet im Auftrag der Kommission für Klinische Kardiologie von Uta C. Hoppe, Erland Erdmann; Köln 2001
32. Madsen EB, Gilpin E, Slutsky RA, Ahnve S, Henning H, Ross J . Usefulness of the chest x-ray for predicting abnormal left ventricular function after acute myocardial infarction. *Am Heart J* 1984; 108: 1431-6.
33. Cohn JN, Archibald DG, Ziesche S Franciosa JA, Harston WE, Tristani FE, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure. *N Engl J Med* 1986; 314: 1547-52.
34. CIBIS Investigators and Committees. A randomized trial of beta-blockade in heart failure. *Circulation* 1994; 90: 1765-73.
35. CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study (CIBIS-II): a randomised trial. *Lancet* 1999; 353: 9-13.
36. Philbin EF, Garg R, Danisa K, Denny M, Gosselin G, Hassapoyannes C, et al. The relationship between cardiothoracic ratio and left ventricular ejection fraction in congestive heart failure. *Digitalis Investigation Group. Arch Intern Med* 1998; 158: 501-6.
37. Davie AP, Francis CM, Love MP, Caruana L, Starkey IR, Shaw TR, et al. Value of the electrocardiogram in identifying heart failure due to left ventricular systolic dysfunction. *BMJ* 1996; 312: 222.
38. Christian TF, Miller TD, Chareonthaitawee P, Hodge DO, O'Connor MK, Gibbons RJ. Prevalence of normal resting left ventricular function with normal rest electrocardiograms. *Am J Cardiol* 1997; 79: 1295-8.
39. Rihal CS, Davis KB, Kennedy JW, Gersh BJ. The utility of clinical, electrocardiographic, and roentgenographic variables in the prediction of left ventricular function. *Am J Cardiol* 1995; 75: 220-3
40. Choy AM, Darbar D, Lang CC, Pringle TH, McNeill GP, Kennedy NS, et al. Detection of left ventricular dysfunction after acute myocardial infarction-comparison of clinical, echocardiographic, and neurohormonal methods. *Br Heart J* 1994; 72: 16-22.

41. Willenheimer RB, Israelsson BA, Cline CM, Erhardt LR. Simplified echocardiography in the diagnosis of heart failure. *Scand Cardiovasc J* 1997; 31: 9-16
42. Colquhoun MC, Waine C, Monaghan MJ, Struthers AD, Mills PG. Investigation in general practice of patients with suspected heart failure: how should the essential echocardiographic service be delivered? *Br J Gen Pract* 1995; 45: 517-9.
43. Patterson JH, Adams KF, Applefeld MM, Corder CN, Masse BR. Oral torsemide in patients with chronic congestive heart failure: effects on body weight, edema, and electrolyte excretion. *Pharmacotherapy* 1994; 14: 514-21.
44. Sherman LG, Liang CS, Baumgardner S, Charuzi Y, Chardo F, Kim CS. Piretanide, a potent diuretic with potassium-sparing properties, for the treatment of congestive heart failure. *Clin Pharmacol Ther* 1986; 40: 587-94.
45. Pehrsson SK. Multicentre comparison between slow release furosemide and bendroflumethiazide in congestive heart failure. *Eur J Clin Pharmacol* 1985; 28: 235-9.
46. Vermeulen A, Chadha DR. Slow release furosemide and hydrochlorothiazide in congestive cardiac failure: a controlled trial. *J Clin Pharmacol* 1982; 22: 513-9.
47. Channer KS, McLean KA, Lawson-Matthew P, Richardson M. Combination diuretic treatment in severe heart failure: a randomised controlled trial. *Br Heart J* 1994; 71: 146-50.
48. Pitt, B., F. Zannad, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. *N Engl J Med* 1999; 341(10): 709-17.
49. Cohn JN, Johnson G, Ziesche S, Cobb F, Francis G, Tristani F, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. *N Engl J Med* 1991; 325: 303-10.
50. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. *N Engl J Med* 1991; 325: 293-302.
51. Cohn JN, Archibald DG, Ziesche S, Franciosa JA, Harston WE, Tristani FE, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure. *N Engl J Med* 1986; 314: 1547-52.
52. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). *N Engl J Med* 1987; 316: 1429-35.
53. Pitt B, Segal R, Martinez FA, Meurers G, Cowley AJ, Thomas I, et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). *Lancet* 1997; 349: 747-52
54. Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. *JAMA* 1995; 273: 1450-6.
55. Packer, M., P. A. Poole-Wilson, et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. *Circulation* 1999; 100 (23): 2312-8.
56. Kober L, Torp-Pedersen C, Carlsen JE, Bagger H, Eliassen P, Lyngborg K, et al. A clinical trial of the angiotensin converting enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. *N Engl J Med* 1995; 333: 1670-6.
57. The AIRE Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. *Lancet* 1993; 342: 821-8.
58. Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJ, Cuddy TE, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. *N Engl J Med* 1992; 327: 669-77.
59. Heidenreich PA, Lee TT, Massie BM. Effect of beta-blockade on mortality in patients with heart failure: A meta-analysis of randomized clinical trials. *J Am Coll Cardiol* 1997; 30: 27-34.
60. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. *N Engl J Med* 1996; 334: 1349-55.
61. Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic

heart disease. Australia/New Zealand Heart Failure Research Collaborative Group. *Lancet* 1997; 349: 375-80.

62. MERIT.HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL randomised intervention trial in congestive heart failure (MERIT.HF). *Lancet* 1999;353:2001-7.

63. The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. *N Engl J Med* 1997; 336: 525-33.

64. Packer M, Gheorghide M, Young JB, Costantini PJ, Adams KF, Cody RJ, et al. Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors. *N Engl J Med* 1993; 329: 1-7.

65. Uretsky BF, Young JB, Shalidi FE, Yellen LG, Harrison MC, Jolly MK. Randomized study assessing the effect of digoxin withdrawal in patients with mild to moderate chronic congestive heart failure: results of the PROVED Trial. *J Am Coll Cardiol* 1993; 22: 955-62.

66. Kostis JB, Shelton B, Gosselin G, Goulet C, Hood WB, Kohn RM, et al. Adverse effects of enalapril in the Studies of Left Ventricular Dysfunction (SOLVD). *Am Heart J* 1996; 131: 350-5.

67. Crozier I, Ikram H, Awan N, Cleland J, Stephen N, Dickstein K, et al. Losartan in heart failure. Haemodynamic effects and tolerability. Losartan Hemodynamic Study Group. *Circulation* 1995; 91: 691-7.

68. Dickstein K, Chang P, Willenheimer R, Haunso S, Remes J, Hall C, et al. Comparison of the effects of losartan and captopril on clinical status and exercise performance in patients with moderate or severe chronic heart failure. *J Am Coll Cardiol* 1995; 26: 438-45.

69. Lang RM, Elkayam U, Yellen LG, Krauss D, McKelvie RS, Vaughan DE, et al. Comparative effects of losartan and enalapril on exercise capacity and clinical status in patients with heart failure. The Losartan Pilot Exercise Study Investigators. *J Am Coll Cardiol* 1997; 30: 983-91.

70. Brixius K, Frank K, Münch G, Müller- Ehmsen J, Schwinger RHG, (1998) WS 1442 (Crataegus-Spezialextrakt) wirkt am menschlichen Myocard kontraktionskraftsteigernd. *Herz/Kreislauf* 30: 28 – 33

71. Leuchtgens H (1992) Crataegus- Spezialextrakt WS 1442 bei Herzinsuffizienz II. *Fortschr Med* 111: 352-354
O'Connolly M, Bernhöft G, Bartsch G (1987) Behandlung älterer, multimorbider Patienten mit stenokardischen Beschwerden. *Therapiewoche* 37: 3587- 3600

72. Packer M, O'Connor CM, Ghali JK, Pressler ML, Carson PE, Belkin RN et al. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group. *N Engl J Med* 1996; 335: 1107-14.

73. Doughty RN, Rodgers A, Sharpe N, MacMahon S. Effects of beta-blocker therapy on mortality in patients with heart failure. A systematic overview of randomized controlled trials. *Eur Heart J* 1997; 18: 560-5.

74. Jaeschke R, Oxman AD, Guyatt GH. To what extent do congestive heart failure patients in sinus rhythm benefit from digoxin therapy? A systematic overview and meta-analysis. *Am J Med* 1990; 88: 279-86

75. Costanzo MR, Augustine S, Bourge R, Bristow M, O'Connell JB, Driscoll D, et al. Selection and treatment of candidates for heart transplantation. A statement for health professionals from the Committee on Heart Failure and Cardiac Transplantation of the Council on Clinical Cardiology, American Heart Association. *Circulation* 1995; 92: 3593-612.

76. Thompson ME, Wallwork J. Recipient selection and assessment; indications for transplantation. In: Wallwork J, Editor. *Heart and heart-lung transplantation*. Philadelphia: Saunders; 1988; p 87-100.

77. The Registry of the International Society for Heart and Lung (1992) Ninth official report 1992. *J Heart Lung Transplant* 11: 599- 606

78. Haywood GA, Rickenbacher PR, Trindade PT, Gullestad L, Jiang JP, Schroeder JS, et al. Analysis of deaths in patients awaiting heart transplantation: impact on patient selection criteria. *Heart* 1996; 75: 455-62.

79. Chen JM, Weinberg AD, Rose EA, Thompson SM, Mancini DM, Ellison JP, et al. Multivariate analysis of factors affecting waiting time to heart transplantation. *Ann Thorac Surg* 1996; 61: 570-5.

80. Arzneimittelkommission der deutschen Ärzteschaft (AKDÄ). Therapieempfehlungen „Chronische Herzinsuffizienz“ 2001. 2. Auflage, Köln.

81. Lee AP, Ice R, Blessey R, Sanmarco ME. Long-term effects of physical training on coronary patients with impaired ventricular function. *Circulation* 1979; 60: 1519-26.

82. Ehsani AA. Adaptations to training in patients with exercise induced left ventricular dysfunction. *Adv Cardiol* 1986; 35: 148-55.

83. Sullivan MJ, Higginbotham MB, Cobb FR. Exercise training in patients with chronic heart failure delays ventilatory anaerobic threshold and improves submaximal exercise performance. *Circulation* 1989; 79: 324-9.
84. Jette M, Heller R, Landry F, Blumchen G. Randomised four week exercise programme in patients with impaired left ventricular function. *Circulation* 1991; 84: 1561-7.
85. Coats AJ, Adamopoulos S, Radaelli A, McCance A, Meyer TE, Bernardi L, et al. Controlled trial of physical training in chronic heart failure. Exercise performance, hemodynamics, ventilation and autonomic function. *Circulation* 1992; 85: 2119-31.
86. McKelvie RS, Teo KK, McCartney N, Humen D, Montague T, Yusuf S. Effects of exercise training in patients with congestive heart failure - A critical review. *J Am Coll Cardiol* 1995; 25: 789-96.
87. Meyer K, Schwaibold M, Westbrook S, Beneke R, Hajric R, Gornandt L, et al. Effects of short-term exercise training and activity restriction on functional capacity in patients with severe chronic congestive heart failure. *Am J Cardiol* 1996; 78: 1017-22.
88. Keteyian SJ, Levine AB, Brawner CA, Kataoka T, Rogers FJ, Schairer JR, et al. Exercise training in patients with heart failure - A randomized controlled trial. *Ann Intern Med* 1996; 124: 1051-7.
89. Bittner V, Weiner DH, Yusuf S, Rogers WJ, McIntyre KM, Bangdiwala SI, et al. Prediction of mortality and morbidity with a 6-minute walk test in patients with left-ventricular dysfunction. *JAMA* 1993; 270: 1702-7
90. Petersen P, Boysen G, Godtfredsen J, Andersen ED, Andersen B. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFSAK Study. *Lancet* 1989; 1:175-9.
91. Kiilavuori K, Toivonen L, Naveri H, Leinonen H. Reversal of autonomic derangements by physical training in chronic heart failure assessed by heart rate variability. *Eur Hear J* 1995; 16: 490-5.
92. Hambrecht R, Niebauer J, Fiehn E, Kalberer B, Offner B, Hauer K, et al. Physical training in patients with stable chronic heart failure: effects on cardiorespiratory fitness and ultrastructural abnormalities of leg muscles. *J Am Coll Cardio* 1995; 25: 1239-49.
93. Coats AJ. Exercise rehabilitation in chronic heart failure. *J Am Coll Cardiol* 1993; 22: 172A-177A.
94. Koch M, Douard H, Broustet JP. The benefit of graded physical exercise in chronic heart failure. *Chest* 1992; 101: 231S-5S.
95. Kavanagh T, Myers MG, Baigrie RS, Mertens DJ, Sawyer P, Shephard RJ. Quality of life and cardiorespiratory function in chronic heart failure: effects of 12 months aerobic training. *Heart* 1996; 76: 42-9.
96. Coats AJ, Adamopoulos S, Meyer TE, Conway J, Sleight P. Effects of physical training in chronic heart failure. *Lancet* 1990; 335: 63-6.
97. Conway N. Haemodynamic effects of ethyl alcohol in coronary heart disease. *Br Heart J* 1968; 76: 581-2.
98. Jacob AJ, McLaren KM, Boon NA. Effects of abstinence on alcoholic heart muscle disease. *Am J Cardiol* 1991; 68: 805-7.
99. Nicolozakes AW, Binkley PF, Leier CV. Haemodynamic effects of smoking in congestive heart failure. *Am J Med Sci* 1988; 296: 377-80.
100. Silagy C, Mant D, Fowler G, Lodge M. Meta-analysis on efficacy of nicotine replacement therapies in smoking cessation. *Lancet* 1994; 343: 139-42.
101. Fiore MC, Smith SS, Jorenby DE, Baker TB. The effectiveness of the nicotine patch for smoking cessation. A meta-analysis. *JAMA* 1994; 271: 1940-7.
102. Nichol KL, Margolis KL, Wuorenma J, Von Sternberg T. The efficacy and cost effectiveness of vaccination against influenza among elderly persons living in the community. *N Engl J Med* 1994; 331: 778-84.
103. Opasich C, Febo O, Riccardi PG, Traversi E, Forni G, Pinna G, et al. Concomitant factors of decompensation in chronic in heart failure. *Am J Cardiol* 1996; 78: 354-7.
104. Ghali JK, Kadakia S, Cooper R, Ferlinz J. Precipitating factors leading to decompensation of heart failure. Traits among urban blacks. *Arch Intern Med* 1988; 148: 2013-6.
105. Antonios TFT, MacGregor GA. Salt - more adverse effects. *Lancet* 1996; 348: 250-1.
106. Sonne-Holm S, Sorenson TI, Jensen G, Schnohr P. Independent effects of weight change and attained

body weight on prevalence of arterial hypertension in obese and non obese men. *BMJ* 1989; 299: 767-70.

107. Kostis JB, Rosen RC, Brondolo E, Taska L, Smith DE, Wilson AC. Superiority of non pharmacologic therapy compared to propranolol and placebo in men with mild hypertension: a randomised prospective trial. *Am Heart J* 1992; 123: 466-74.

108. Reisin E, Abel R, Modan M, Silverberg DS, Eliahou HE, Modan B. Effect of weight loss without salt restriction on the reduction of blood pressure in overweight hypertensive patients. *N Engl J Med* 1978; 298: 1-6.

109. Dattilo AM, Kris-Etherton PM. Effects of weight reduction on blood lipids and lipoproteins: a meta-analysis. *Am J Clin Nutr* 1992; 56: 320-8.

110. Hankey CR, Rumley A, Lowe GD, Lean ME. Weight loss improves established indices of ischaemic heart disease risk [abstract]. *Proc Nutr Soc* 1995; 54(Pt2): 94A.

111. Freeman LM, Roubenoff R. The nutritional implications of cardiac cachexia. *Nutr. Rev* 1994; 52: 340-7.

112. Anker SD, Ponikowski P, Varney S, Chua TP, Clark AL, Webb-Peploe KM, et al. Wasting as independent risk factor for mortality in chronic heart failure. *Lancet* 1997; 349: 1050-3.

113. Endres S, Ghorbani R, Kelly VE, Georgilis K, Lonnemann G, van der Meer JW, et al. The effect of dietary supplementation with n-3 polyunsaturated fatty acids on the synthesis of interleukin-1 and tumour necrosis factory by mononuclear cells . *N Engl J Med* 1989; 320: 265-71.

114. Seligmann H, Halkin H, Rauchfleisch S, Kaufmann N, Motro M, Vered Z, et al. Thiamine-deficiency in patients with congestive heart failure receiving long term furosemide therapy: a pilot study. *Am J Med* 1991; 91: 151-5.

115. Kwok T, Falconer-smith JF, Potter JF, Ives DR. Thiamine status of elderly patients with cardiac failure. *Age Ageing* 1992; 21: 67-71.

116. Pfitzenmeyer P, Guillard JC, d'Athis P, Petit-Marnier C, Gaudet M. Thiamine status of elderly patients with cardiac failure including the effects of supplementation. *Int J Vitam Nutr Res* 1994; 64: 113-8

117. Shimon I, Almog S, Vered Z, Seligmann H, Shefi M, Peleg E, et al. Improved left ventricular function after thiamine supplementation in patients with congestive heart failure receiving long term furosemide therapy. *Am J Med* 1995; 98: 485-90

118. Nikolaus T, Specht-Leible N, Kruse W, Oster P, Schlierf G. Early rehospitalization of very elderly patients – causes and prevention. *Dtsch Med Wochenschr* 1992; 117: 403-7.

119. Chin MH, Goldman L. Factors contributing to the hospitalization of patients with congestive heart failure. *Am J Public Health* 1997; 87: 643-8.

120. Chin MH, Goldman L. Correlates of early hospital readmission or death in patients with congestive heart failure. *Am J Cardiol* 1997; 79: 1640-4.

121. Wagdi P, Vuillomenet A, Kaufmann U, Richter M, Bertel O. [Inadequate treatment compliance, patient information and drug prescription as causes for emergency hospitalization of patients with chronic heart failure]. *Schweiz Med Wochenschr* 1993; 123: 108-12.

122. Rich MW, Beckham V, Wittenberg C, Leven CL, Freedland KE, Carney RM. A multidisciplinary intervention to prevent the readmission of elderly patients with congestive heart failure. *N Engl J Med* 1995; 333: 1190-5

123. Kornowski R, Zeeli D, Auerbach M, Finkelstein A, Schwartz D, Moshkovitz M et al. Intensive home care surveillance prevents hospitalisation and improves morbidity rates among elderly patients with severe congestive heart failure. *Am Heart J* 1995; 129: 762-6.

124. Stewart S, Pearson S, Horowitz JD. Effects of a home-based intervention among patients with congestive heart failure discharged from acute hospital care. *Arch Intern Med* 1998; 158: 1067-72.

125. Stewart S, Vandenbroek AJ, Pearson S, Horowitz JD. Prolonged beneficial effects of a home-based intervention on unplanned readmissions and mortality among patients with congestive heart failure. *Arch Int Med* 1999; 159: 257-61.

126. West JA, Miller NH, Parker KM, Senneca D, Ghandour G, Clark M, et al. A comprehensive management system for heart failure improves clinical outcomes and reduces medical resource utilisation. *Am J Cardiol* 1997; 79: 58-63.

127. Smith LE, Fabbri SA, Pai R, Ferry D, Heywood JT. Symptomatic improvement and reduced hospitalization for patients attending a cardiomyopathy clinic. *Clin Cardiol* 1997; 20: 949-54.

128. Fonarow GC, Stevenson LW, Walden JA, Livingston NA, Steimle AE, Hamilton MA. Impact of a comprehensive heart failure management program on hospital readmission and functional status of patients with advanced heart failure. *J Am Coll Cardiol* 1997; 30: 725-32.
129. Vinson JM, Rich MW, Sperry JC, Shah AS, McNamara T. Early readmission of elderly patients with congestive heart failure. *J Am Geriatr Soc* 1990; 38: 1290-5.
130. Monane M, Bohn RL, Gurwitz JH, Glynn RJ, Avorn J. Noncompliance with congestive heart failure therapy in the elderly. *Arch Int Med* 1994; 154: 433-7.
131. Rich MW, Gray DB, Beckham V, Wittenberg C, Luther P. Effect of multidisciplinary intervention on medication compliance in elderly patients with congestive heart failure. *Am J Med* 1996; 101: 270-6.
132. Goodyer LI, Miskelly F, Milligan P. Does encouraging good compliance improve patients clinical condition in heart failure? *Br J Clin Pract* 1995; 49: 173-6.
133. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigators. *N Engl J Med* 1992; 327: 685-91.
134. Hall A S, Murray GD, Ball SG. on behalf of the AIREX Study Investigators (1997). Follow-up study of patients randomly allocated ramipril or placebo for heart failure after acute myocardial infarction: AIRE Extensions (AIREX) Study. *Lancet* 345: 669-685
135. Kostis JB, Rosen RC, Cosgrove NM, Schindler DM, Wilson AC. Nonpharmacological therapy improves functional and emotional status in congestive heart failure. *Chest* 1994; 106: 996-1001.
136. Keteyiann SJ, et al. Exercise training in patients with heart failure: a randomized controlled trial. *Ann Intern Med.* 1996;124:1051–1057.
137. Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALES]). *Am J Cardiol* 1996; 78 (8): 902-7.
138. Dahlstrom, U. and E. Karlsson. Captopril and spironolactone therapy for refractory congestive heart failure. *Am J Cardiol.* 1993; 71(3): 29A-33A.
139. van Vliet, A. A., A. J. Donker, et al. Spironolactone in congestive heart failure refractory to high-dose loop diuretic and low-dose angiotensin-converting enzyme inhibitor. *Am J Cardiol* 1993; 71(3): 21A-28A.
140. Dunkman, W. B., G. R. Johnson, et al. Incidence of thromboembolic events in congestive heart failure. The V- HeFT VA Cooperative Studies Group. *Circulation* 1993; 87 (6 Suppl): VI94-101.
141. Al-Khadra, A. S., D. N. Salem, et al. Warfarin anticoagulation and survival: a cohort analysis from the Studies of Left Ventricular Dysfunction. *J Am Coll Cardiol* 1998; 31(4): 749-53.
142. Pullicino, P. M., J. L. Halperin, et al. Stroke in patients with heart failure and reduced left ventricular ejection fraction. *Neurology* 2000; 54 (2): 288-94.
143. Spaulding, C., B. Charbonnier, et al. Acute hemodynamic interaction of aspirin and ticlopidine with enalapril: results of a double-blind, randomized comparative trial. *Circulation* 1998; 98 (8): 757-65.
144. Leor, J., H. Reicher-Reiss, et al. Aspirin and mortality in patients treated with angiotensin-converting enzyme inhibitors: a cohort study of 11,575 patients with coronary artery disease. *J Am Coll Cardiol* 1999; 33 (7): 1920-5
145. Cohn, J. N. and G. Tognoni. Effect of the Angiotensin Receptor Blocker Valsartan on Morbidity and Mortality in Heart Failure: the Valsartan Heart Failure Trial (Va-HeFT) [Abstract]. *Circulation* 2000; 102 (21): b2672.
146. Recommendations for exercise testing in chronic heart failure patients. *Eur Heart J* 2001; 22 (1): 37-45.
147. Recommendations for exercise training in chronic heart failure patients. *Eur Heart J* 2001; 22(2): 125-135.
148. Grady, K. L., K. Dracup, et al. Team management of patients with heart failure: A statement for healthcare professionals from The Cardiovascular Nursing Council of the American Heart Association. *Circulation* 2000; 102 (19): 2443-56.
149. Cazeau S, Leclercq C, Lavergne T et al. for The Multisite Stimulation in Cardiomyopathies (MUSTIC) Study Investigators. *N Engl J Med* 2001;344:873-880
150. Foster AH, Gold MR, McLaughlin JS. Acute hemodynamic effects of atrio-biventricular pacing in humans. *Ann Thorac Surg* 1995;59:294-300

151. Leclercq C, Cazeau S, Le Breton H et al. Acute hemodynamic effects of biventricular DDD pacing in patients with end-stage heart failure. J Am Coll Cardiol 1998;32:1825-1831
152. El-Banayosy A, Fey O, Sarnowski P, et al . Midterm follow-up of patients discharged from hospital under left ventricular assistance. J Heart Lung Transplant 2001; 20:53-8
153. Griffith BP, Kormos RL, Borovetz HS, et al. HeartMate II left ventricular assist system: from concept to first clinical use. Ann Thorac Surg 2001; 71(3 Suppl):S116-20
154. Goldstein DJ, Oz MC, Rose EA. Implantable left ventricular assist devices. N Engl J Med 1998;339:1522-1533
155. Starling RC, McCarthy PM, Buda T et al. Results of partial left ventriculectomy for dilated cardiomyopathy. J Am Coll Cardiol 2000;36:2098-2103
156. Batista RJV, Santos JLV, Takeshita N et al. Partial left ventriculectomy to improve left ventricular function in end-stage heart disease. J Card Surg 1996;11:96-97
157. Di Mattia DG, Di Biasi P, Salati M et al. Surgical treatment of left ventricular post-infarction aneurysm with endoventriculoplasty: late clinical and functional results. Eur J Cardiothorac Surg 1999 Apr;15:413-8

[\[Algorithmus\]](#)
[\[Diagnose Text\]](#)
[\[Therapie Text\]](#)
[\[Referenzen\]](#)
[\[Patientenleitlinie\]](#)
[\[Impressum/ ©\]](#)

[\[Start Leitlinien\]](#) [\[» Asthma\]](#) [\[» Kopfschmerzen\]](#) [\[» Hypertonie\]](#) [\[» Otitis media\]](#) [\[» Gallensteine\]](#) [\[» Herzinsuffizienz\]](#)
[\[Algorithmus\]](#) [\[Diagnose Text\]](#) [\[Therapie Text\]](#) [\[Referenzen\]](#) [\[Patientenleitlinie\]](#) [\[Impressum/ ©\]](#) [\[» Demenz\]](#)
[\[» Harnwegsinfekt\]](#) [\[» KR-Karzinom\]](#) [\[» Dekubitus\]](#) [\[Ihre Meinung?\]](#) [\[Interne Infos\]](#)

Sch
Te
V
sam
F
Mediz